Study ID | Intervention | Control | Outcome | Included studies | No. of participants | Summary estimate | Effects size | Heterogeneity |
Death | ||||||||
Nagasaka et al71 | Pulse CYC | Continuous CYC | Death at 1 year | 3 RCT | 246 | RR (95% CI) | 0.47 (0.23 to 0.99) | I2=0% |
Springer et al16 | Pulse CYC | Continuous CYC | Mortality | 4 RCT | 296 | OR (95% CI) | 0.56 (0.29 to 1.07) | I2=0% |
Walters et al15 | Pulse CYC | Continuous CYC | Death at final FU | 4 RCT | 278 | RR (95% CI) | 0.77 (0.44 to 1.32) | I2=15% |
Remission | ||||||||
Nagasaka et al71 | Pulse CYC | Continuous CYC | Remission | 3 RCT | 246 | RR (95% CI) | 1.07 (0.96 to 1.19) | I2=15% |
Walters et al15 | Pulse CYC | Continuous CYC | Remission at 6 months | 2 RCT | 176 | RR (95% CI) | 1.03 (0.93 to 1.13) | I2=0% |
Relapse | ||||||||
Springer et al16 | Pulse CYC | Continuous CYC | Relapse | 4 RCT | 284 | OR (95% CI) | 2.04 (1.11 to 3.75) | I2=0% |
Walters et al15 | Pulse CYC | Continuous CYC | Relapse at end of FU | 4 RCT | 235 | RR (95% CI) | 1.79 (1.11 to 2.87) | I2=0% |
Leucopenia | ||||||||
Springer et al16 | Pulse CYC | Continuous CYC | Leucopenia | 3 RCT | 250 | OR (95% CI) | 0.37 (0.20 to 0.69) | I2=16% |
Walters et al15 | Pulse CYC | Continuous CYC | Leucopenia | 4 RCT | 278 | RR (95% CI) | 0.53 (0.36 to 0.77) | I2=0% |
Serious infection | ||||||||
Nagasaka et al71 | Pulse CYC | Continuous CYC | Serious infection | 3 RCT | 246 | RR (95% CI) | 0.56 (0.37 to 0.86) | I2=0% |
Walters et al15 | Pulse CYC | Continuous CYC | Serious infection | 4 RCT | 278 | RR (95% CI) | 0.71 (0.38 to 1.33) | I2=71% |
I2 refers to the proportion of overall variability that rises from between-study heterogeneity.
CYC, cyclophosphamide; FU, follow-up; GPA, granulomatosis with polyangiitis; MPA, microscopic polyangiitis; RCT, randomised controlled trial; RR, risk ratio.